Tradewinds Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Tradewinds Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-100	Closed	-$2K	–	693
2020 Q2	$2K	Hold	100	–	–	﹤0.01%	566
2020 Q1	$1K	Sell	100 -112	-53%	-$1.51K	﹤0.01%	606
2019 Q4	$3K	Buy	212 +60	+39%	+$835	﹤0.01%	561
2019 Q3	$2K	Hold	152	–	–	﹤0.01%	536
2019 Q2	$2K	Hold	152	–	–	﹤0.01%	534
2019 Q1	$3K	Sell	152 -112	-42%	-$1.67K	﹤0.01%	507
2018 Q4	$4K	Buy	264 +30	+13%	+$558	﹤0.01%	496
2018 Q3	$7K	Hold	234	–	–	﹤0.01%	459
2018 Q2	$6K	Sell	234 -15	-6%	-$363	﹤0.01%	476
2018 Q1	$5K	Hold	249	–	–	﹤0.01%	481
2017 Q4	$5K	Hold	249	–	–	﹤0.01%	506
2017 Q3	$6K	Hold	249	–	–	﹤0.01%	466
2017 Q2	$4K	Buy	249 +1	+0.4%	+$14	﹤0.01%	505
2017 Q1	$3K	Hold	248	–	–	﹤0.01%	549
2016 Q4	$3K	Sell	248 -1,903	-88%	-$28.6K	﹤0.01%	505
2016 Q3	$37K	Buy	+2,151	New	+$41.6K	0.03%	232

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tradewinds Capital Management's NTLA Position: Q3 2020 in Review

Tradewinds Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2020, closing a stake of 100 shares — an estimated $2K sold.

Tradewinds Capital Management first reported a position in NTLA in Q3 2016 and held it in 16 quarters. The position peaked at $37K in Q3 2016. 165 funds tracked by Wall St. Rank hold NTLA as of Q3 2020.

Tradewinds Capital Management reported no remaining Intellia Therapeutics position as of Q3 2020 after selling out during the quarter.
Tradewinds Capital Management sold 100 Intellia Therapeutics shares in Q3 2020, an estimated $2K.
Tradewinds Capital Management first reported a position in Intellia Therapeutics in Q3 2016 and held it in 16 quarters.
Tradewinds Capital Management's Intellia Therapeutics position peaked at $37K in Q3 2016.
165 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2020.

Based on Tradewinds Capital Management's 13F filing for Q3 2020, filed 26 Oct 2020.